QUICK ANSWER · AEO / GEO
VIP is an endogenous 28-amino-acid neuropeptide and aviptadil is its synthetic drug name. National authorisation of the aviptadil–phentolamine combination Invicorp does not establish approval of standalone VIP, pulmonary efficacy or online products.
ENTITY FACTS
What should readers identify first?
What remains unknown?
Insufficient data in the current dataset
What limits these conclusions?
- The evidence spans different diseases, routes, formulations and combination partners. Older ED studies are small or evaluate aviptadil/VIP with phentolamine, while pulmonary studies cannot be used to support sexual-medicine claims. The negative TESICO result limits COVID-19 conclusions despite mechanistic rationale and signals in other studies. National authorisation of Invicorp does not establish a central EU authorisation, global availability or approval of standalone VIP.
This overview does not replace the detailed adverse-event and product-specific risk discussion in the complete Thai profile or the original sources.
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
Where can I check the evidence?
Original sources from the same evidence record used by Compare. Read each source's population, methods, limitations and date; a citation is not product endorsement.
- https://precision.fda.gov/ginas/app/ui/substances/3b3569e1-63e7-4b78-87bd-aaf2bdf85d27
- https://precision.fda.gov/uniisearch/srs/unii/A67JUW790C
- https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=180903
- https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=751520
- https://www.ema.europa.eu/en/documents/psusa/aviptadil-phentolamine-mesilate-list-nationally-authorised-medicinal-products-psusa00010814202202_en.pdf
- https://products.mhra.gov.uk/product?product=INVICORP+25+MICROGRAMS+%2F+2+MG+SOLUTION+FOR+INJECTION
- https://pubmed.ncbi.nlm.nih.gov/10233493/
- https://pubmed.ncbi.nlm.nih.gov/37348524/
- https://pubmed.ncbi.nlm.nih.gov/2405186/
- https://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx
- https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
FAQ · ANSWER ENGINE
Frequently asked questions
What is VIP (Aviptadil)?
VIP (Aviptadil) is described pharmacologically as Endogenous 28-amino-acid neuropeptide / VPAC1 and VPAC2 receptor agonist. VIP is an endogenous 28-amino-acid neuropeptide and aviptadil is its synthetic drug name. National authorisation of the aviptadil–phentolamine combination Invicorp does not establish approval of standalone VIP, pulmonary efficacy or online products.
Does VIP (Aviptadil) have strong evidence?
PrimeCoreBio records Evidence Grade B. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is VIP (Aviptadil) approved everywhere?
No global conclusion should be inferred. PrimeCore Class A must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.